Maximum Strength Mucus D Tablet, Extended Release
NDC Package 51316-970-24

View Billable Units, 11-Digit Conversion Format, and RxNorm mappings

Package Information

Maximum Strength Mucus D (guaifenesin and pseudoephedrine hydrochloride) tablets is do not crush, chew, or break extended-release tablettake with a full glass of waterthis product can be administered without regard for timing of mealsadults and children 12 years and older: 1 extended-release tablet every 12 hours; not more than 2 extended-release tablets in 24 hourschildren under 12 years of age: do not use. This formulation utilizes a tablet, extended release delivery system. Marketed by Cvs Pharmacy, this product is identified by NDC 51316-970 and is authorized under FDA application ANDA212542.

Identification & Billing

NDC Package Code
51316-970-24
Package Description
1 BLISTER PACK in 1 CARTON / 24 TABLET, EXTENDED RELEASE in 1 BLISTER PACK
Product Code
11-Digit Billing Format
51316097024
RxNorm Crosswalk
  • RxCUI: 1244675 - guaiFENesin 1200 MG / pseudoephedrine HCl 120 MG 12HR Extended Release Oral Tablet
  • RxCUI: 1244675 - 12 HR guaifenesin 1200 MG / pseudoephedrine hydrochloride 120 MG Extended Release Oral Tablet

Clinical Specifications

Proprietary Name
Maximum Strength Mucus D
Non-Proprietary Name
Guaifenesin And Pseudoephedrine Hydrochloride
Substance Name
Guaifenesin; Pseudoephedrine Hydrochloride
Dosage Form
Tablet, Extended Release - A solid dosage form containing a drug which allows at least a reduction in dosing frequency as compared to that drug presented in conventional dosage form.
Administration Route
Oral - Administration to or by way of the mouth.
Usage Information
Do not crush, chew, or break extended-release tablettake with a full glass of waterthis product can be administered without regard for timing of mealsadults and children 12 years and older: 1 extended-release tablet every 12 hours; not more than 2 extended-release tablets in 24 hourschildren under 12 years of age: do not use

Regulatory & Marketing

Labeler Name
Cvs Pharmacy
Product Type
Human Otc Drug
FDA Application #
ANDA212542
Marketing Category
ANDA - A product marketed under an approved Abbreviated New Drug Application.
Start Marketing Date
08-10-2022
Listing Expiration
12-31-2026
Exclude Flag
N
Sample Package
No

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 51316-970-24 identifies a specific commercial package of 1 blister pack in 1 carton / 24 tablet, extended release in 1 blister pack of Maximum Strength Mucus D, a human over the counter drug labeled by Cvs Pharmacy. This tablet, extended release is formulated for oral use and contains guaifenesin; pseudoephedrine hydrochloride as the active substance.

Is this product currently listed with the FDA?

Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Cvs Pharmacy on August 10, 2022. The current certification is valid through December 31, 2026.

How is this Cvs Pharmacy product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 51316097024. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (5-3-2)
51316-970-24
11-Digit CMS (5-4-2)
51316-0970-24

Note: The zero is added to the Product segment to maintain the 5-4-2 structure.